Jump to content

Lipid II: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Citation bot (talk | contribs)
Bots
5,442,433 edits
Added url. | Use this bot. Report bugs. | Suggested by Graeme Bartlett | #UCB_toolbar
 
(26 intermediate revisions by 11 users not shown)
Line 1: Line 1:
{{short description|Chemical compound}}
{{chembox
{{chembox
| verifiedrevid =
| verifiedrevid =
| ImageFile = Lipid II structure.svg
| ImageFile = Lipid II structure.svg
| ImageSize = 360px
| ImageSize = 360px
| SystematicName = (2''R'',5''R'',8''S'',13''R'',16''S'',19''R'')-19-{[(2''R'',3''R'',4''R'',5''S'',6''R'')-3-Acetamido-5-{[(2''S'',3''R'',4''R'',5''S'',6''R'')-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2-[(1,3-dihydroxy-1,3-dioxo-3-{[(2''Z'',6''Z'',10''Z'',14''Z'',18''Z'',22''Z'',26''Z'',30''Z'',34''E'',38''E'',42''E'')-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaen-1-yl]oxy}-1λ<sup>5</sup>,3λ<sup>5</sup>-diphosphoxan-1-yl)oxy]-6-(hydroxymethyl)oxan-4-yl]oxy}-8-(4-aminobutyl)-13-carboxy-2,5,16-trimethyl-4,7,10,15,18-pentaoxo-3,6,9,14,17-pentaazaicosan-1-oic acid
| IUPACName =
| OtherNames =
| OtherNames =
| Section1 =
| Section1 = {{Chembox Identifiers
| CASNo_Ref = {{Cascite|changed|<ref>{{cite web |last1=Senf |first1=L. |last2=Schmidt |first2=U. |last3=Anger |first3=G. |title=[Clearance computation from the blood level following a single injection of 125-I-hippuran] |url=339578-22-2 |website=Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete |pages=508–513 |date=1 October 1977}}</ref>}}
{{Chembox Identifiers
⚫
| CASNo = 339578-22-2
| CASNo_Ref =
| Beilstein = 9039417
⚫
| CASNo=
| KEGG = C05893
⚫
| PubChem=46173749
| KEGG1 = G10553
⚫
| SMILES=CC(C(=O)NC(CCC(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(C)C(=O)O)C(=O)O)NC(=O)C(C)OC1C(C(OC(C1OC2C(C(C(C(O2)CO)O)O)NC(=O)C)CO)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)NC(=O)C
⚫
| PubChem = 46173749
⚫
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
⚫
| SMILES = CC(C(=O)NC(CCC(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(C)C(=O)O)C(=O)O)NC(=O)C(C)OC1C(C(OC(C1OC2C(C(C(C(O2)CO)O)O)NC(=O)C)CO)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)NC(=O)C
⚫
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 26333143
| ChemSpiderID = 26333143
| ChEBI_Ref =
| ChEBI_Ref =
| ChEBI = 27692
| ChEBI = 27692
⚫
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| InChI =
| InChIKey =
⚫
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C94H156N8O26P2/c1-59(2)31-21-32-60(3)33-22-34-61(4)35-23-36-62(5)37-24-38-63(6)39-25-40-64(7)41-26-42-65(8)43-27-44-66(9)45-28-46-67(10)47-29-48-68(11)49-30-50-69(12)54-56-122-129(118,119)128-130(120,121)127-94-82(100-75(18)106)86(85(79(58-104)125-94)126-93-81(99-74(17)105)84(109)83(108)78(57-103)124-93)123-73(16)89(112)96-71(14)88(111)102-77(92(116)117)52-53-80(107)101-76(51-19-20-55-95)90(113)97-70(13)87(110)98-72(15)91(114)115/h31,33,35,37,39,41,43,45,47,49,54,70-73,76-79,81-86,93-94,103-104,108-109H,19-30,32,34,36,38,40,42,44,46,48,50-53,55-58,95H2,1-18H3,(H,96,112)(H,97,113)(H,98,110)(H,99,105)(H,100,106)(H,101,107)(H,102,111)(H,114,115)(H,116,117)(H,118,119)(H,120,121)/b60-33+,61-35+,62-37-,63-39-,64-41-,65-43-,66-45-,67-47-,68-49-,69-54-/t70-,71+,72-,73-,76+,77-,78-,79-,81-,82-,83-,84-,85-,86-,93+,94-/m1/s1
| StdInChI = 1S/C94H156N8O26P2/c1-59(2)31-21-32-60(3)33-22-34-61(4)35-23-36-62(5)37-24-38-63(6)39-25-40-64(7)41-26-42-65(8)43-27-44-66(9)45-28-46-67(10)47-29-48-68(11)49-30-50-69(12)54-56-122-129(118,119)128-130(120,121)127-94-82(100-75(18)106)86(85(79(58-104)125-94)126-93-81(99-74(17)105)84(109)83(108)78(57-103)124-93)123-73(16)89(112)96-71(14)88(111)102-77(92(116)117)52-53-80(107)101-76(51-19-20-55-95)90(113)97-70(13)87(110)98-72(15)91(114)115/h31,33,35,37,39,41,43,45,47,49,54,70-73,76-79,81-86,93-94,103-104,108-109H,19-30,32,34,36,38,40,42,44,46,48,50-53,55-58,95H2,1-18H3,(H,96,112)(H,97,113)(H,98,110)(H,99,105)(H,100,106)(H,101,107)(H,102,111)(H,114,115)(H,116,117)(H,118,119)(H,120,121)/b60-33+,61-35+,62-37-,63-39-,64-41-,65-43-,66-45-,67-47-,68-49-,69-54-/t70-,71+,72-,73-,76+,77-,78-,79-,81-,82-,83-,84-,85-,86-,93+,94-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ULXTYUPMJXVUHQ-OVTFQNCVSA-N}}
| StdInChIKey = ULXTYUPMJXVUHQ-OVTFQNCVSA-N}}
| Section2 = {{Chembox Properties
| Section2 = {{Chembox Properties
Line 32: Line 33:


'''Lipid II''' is a precursor molecule in the synthesis of the [[cell wall]] of bacteria. It is a [[peptidoglycan]], which is [[amphipathic]] and named for its [[bactoprenol]] hydrocarbon chain, which acts as a lipid anchor, embedding itself in the bacterial [[cell membrane]]. Lipid II must translocate across the cell membrane to deliver and incorporate its disaccharide-pentapeptide "building block" into the peptidoglycan mesh. Lipid II is the target of several [[antibiotics]].
'''Lipid II''' is a precursor molecule in the synthesis of the [[cell wall]] of bacteria. It is a [[peptidoglycan]], which is [[amphipathic]] and named for its [[bactoprenol]] hydrocarbon chain, which acts as a lipid anchor, embedding itself in the bacterial [[cell membrane]]. Lipid II must translocate across the cell membrane to deliver and incorporate its disaccharide-pentapeptide "building block" into the peptidoglycan mesh. Lipid II is the target of several [[antibiotics]].

A number of analogous compounds are produced via a similar pathway in some bacteria, giving rise to cell wall modifications. See [[EC 2.4.1.227]] for more information.<ref>{{cite web |title=MetaCyc EC 2.4.1.227 |url=https://biocyc.org/META/NEW-IMAGE?type=REACTION&object=RXN-22615 |website=biocyc.org}}</ref>


==Synthesis==
==Synthesis==


===In peptidoglycan biosynthetic pathway===
===In peptidoglycan biosynthetic pathway===
Lipid II is the final intermediate in [[peptidoglycan synthesis]]. It is formed when the [[Undecaprenyldiphospho-muramoylpentapeptide beta-N-acetylglucosaminyltransferase|MurG transferase]] catalyzes addition of [[N-acetylglucosamine|''N''-acetylglucosamine]] (GlcNAc) to Lipid I, resulting in a complete disaccharide-pentapeptide monomer with a bactoprenol-pyrophosphate anchor. This occurs on the inside of the cytoplasmic membrane, where the bactoprenol chain is embedded in the inner leaflet of the bilayer. Lipid II is then flipped across the membrane to expose the disaccharide-pentapeptide monomer, which is the pentapeptide stem consisting of L-Ala-γ-D-Glu-m-DAP-D-Ala-D-Ala between GlcNAc and [[N-acetylmuramic acid|''N''-acetylmuramic acid]] (MurNAc), for polymerization and cross-linking into peptidoglycan. The remaining bactoprenol-pyrophosphate is then recycled to the interior of the membrane. Lipid II has been referred to as the "shuttle carrier" of peptidoglycan "building blocks'.<ref name=sim>{{cite journal|author1=Anton Chugunov|author2=Darya Pyrkova|author3=Dmitry Nolde|author4=Anton Polyansky|author5=Vladimir Pentkovsky|author6=Roman Efremov|title=Lipid-II forms potential "landing terrain" for lantibiotics in simulated bacterial membrane|journal=Sci. Rep.|date=Apr 16, 2013| volume=3| pages=1678| doi=10.1038/srep01678|pmid=23588060|pmc=3627190}}</ref>
Lipid II is the final intermediate in [[peptidoglycan synthesis]]. It is formed when the [[Undecaprenyldiphospho-muramoylpentapeptide beta-N-acetylglucosaminyltransferase|MurG transferase]] catalyzes addition of [[N-acetylglucosamine|''N''-acetylglucosamine]] (GlcNAc) to Lipid I, resulting in a complete disaccharide-pentapeptide monomer with a bactoprenol-pyrophosphate anchor. This occurs on the inside of the cytoplasmic membrane, where the bactoprenol chain is embedded in the inner leaflet of the bilayer. Lipid II is then transported across the membrane by a [[flippase]], to expose the disaccharide-pentapeptide monomer, which is the pentapeptide stem consisting of <small>L</small>-Ala-γ-<small>D</small>-Glu-m-DAP-<small>D</small>-Ala-<small>D</small>-Ala between GlcNAc and [[N-acetylmuramic acid|''N''-acetylmuramic acid]] (MurNAc), for polymerization and cross-linking into peptidoglycan. The remaining bactoprenol-pyrophosphate is then recycled to the interior of the membrane. Lipid II has been referred to as the "shuttle carrier" of peptidoglycan "building blocks'.<ref name=sim>{{cite journal|author1=Anton Chugunov|author2=Darya Pyrkova|author3=Dmitry Nolde|author4=Anton Polyansky|author5=Vladimir Pentkovsky|author6=Roman Efremov|title=Lipid-II forms potential "landing terrain" for lantibiotics in simulated bacterial membrane|journal=Sci. Rep.|date=Apr 16, 2013| volume=3| pages=1678| doi=10.1038/srep01678|pmid=23588060|pmc=3627190|bibcode=2013NatSR...3E1678C}}</ref>

The essential [[flippase]] that translocates lipid II across the cytoplasmic membrane was only published in July 2014, after decades of searching.<ref name=science>{{cite journal|author1=Lok-To Sham|author2=Emily K. Butler|author3=Matthew D. Lebar|title=MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis| journal=Science |date=11 July 2014| volume=345| issue=6193| pages=220–222| doi=10.1126/science.1254522|display-authors=etal| pmid=25013077| pmc=4163187}}</ref>
The essential MurJ [[flippase]] that translocates lipid II across the cytoplasmic membrane was only published in July 2014, after decades of searching.<ref name=science>{{cite journal|author1=Lok-To Sham|author2=Emily K. Butler|author3=Matthew D. Lebar|title=MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis| journal=Science |date=11 July 2014| volume=345| issue=6193| pages=220–222| doi=10.1126/science.1254522|display-authors=etal| pmid=25013077| pmc=4163187|bibcode=2014Sci...345..220S}}</ref> The discovery remains somewhat controversial as assay results are conflicting; FtsW ([[EC 2.4.1.129]]) was proposed as an alternative, with evidence strongly favoring the MurJ side since 2019.<ref>{{cite web |title=TCDB 2.A.66.4.3 |url=https://tcdb.org/search/result.php?tc=2.A.66.4.3 |website=tcdb.org}}</ref>


===Artificial production===
===Artificial production===
A method for artificial production of lipid II has been described. For synthesis of lipid II from UDP-MurNAc pentapeptide and undecaprenol, the enzymes [[Phospho-N-acetylmuramoyl-pentapeptide-transferase|MraY]], MurG, and [[undecaprenol kinase]] can be used.<ref name=acie>{{cite journal|vauthors=Huang LY, Huang SH, Chang YC, Cheng WC, Cheng TJ, Wong CH|title=Enzymatic synthesis of lipid II and analogues.|journal=Angew Chem Int Ed Engl|date=28 July 2014| volume=53| issue=31| pages=8060–5.| doi=10.1002/anie.201402313}}</ref>
A method for artificial production of lipid II has been described. For synthesis of lipid II from UDP-MurNAc pentapeptide and undecaprenol, the enzymes [[Phospho-N-acetylmuramoyl-pentapeptide-transferase|MraY]], MurG, and [[undecaprenol kinase]] can be used.<ref name=acie>{{cite journal|vauthors=Huang LY, Huang SH, Chang YC, Cheng WC, Cheng TJ, Wong CH|title=Enzymatic synthesis of lipid II and analogues.|journal=Angew Chem Int Ed Engl|date=28 July 2014| volume=53| issue=31| pages=8060–5| doi=10.1002/anie.201402313|pmid=24990652}}</ref>
Synthetic Lipid II analogues are used in experiments studying how it interacts with and binds molecules.<ref>{{cite journal | title=New Insights into Nisin's Antibacterial Mechanism Revealed by Binding Studies with Synthetic Lipid II Analogues. |vauthors=t Hart P, Oppedijk S, Breukink E, Martin NI | journal=Biochemistry | year=2016 | volume=55 | issue=1 | pages=232–7 | doi=10.1021/acs.biochem.5b01173 | pmid=26653142}}</ref>
Synthetic Lipid II analogues are used in experiments studying how it interacts with and binds molecules.<ref>{{cite journal | title=New Insights into Nisin's Antibacterial Mechanism Revealed by Binding Studies with Synthetic Lipid II Analogues. |vauthors=t Hart P, Oppedijk S, Breukink E, Martin NI | journal=Biochemistry | year=2016 | volume=55 | issue=1 | pages=232–7 | doi=10.1021/acs.biochem.5b01173 | pmid=26653142|url=https://dspace.library.uu.nl/handle/1874/344061 }}</ref>
Significant quantities of the important peptidoglycan precursor have also be isolated, following accumulation in bacterial cells.<ref>{{cite journal | title=Lipid II overproduction allows direct assay of transpeptidase inhibition by b-lactams. |vauthors= Qiao Y, Srisuknimit V, Rubino F, Schaefer K, Nuiz R, Walker S, Kahne D | journal=Nature Chemical Biology | year=2017 | volume=13 | pages=793–798 |
Significant quantities of the important peptidoglycan precursor have also be isolated, following accumulation in bacterial cells.<ref>{{cite journal | title=Lipid II overproduction allows direct assay of transpeptidase inhibition by b-lactams. |vauthors= Qiao Y, Srisuknimit V, Rubino F, Schaefer K, Nuiz R, Walker S, Kahne D | journal=Nature Chemical Biology | year=2017 | volume=13 |issue= 7 | pages=793–798 | doi=10.1038/nchembio.2388 | pmid=28553948| pmc=5478438 }}</ref>
doi:10.1038/nchembio.2388 | pmid=28553948}}</ref>


==Functions==
==Functions==
Polymers of lipid II form a linear [[glycan]] chain. This reaction is catalyzed by the [[glycosyltransferase]]s of family 51 (GT51). [[DD-transpeptidase|Transpeptidase]]s cross link the chains and form a net-like peptidoglycan macromolecule. The resulting glycopeptide is an essential part of the envelope of many bacteria.
Polymers of lipid II form a linear [[glycan]] chain. This reaction is catalyzed by the [[glycosyltransferase]]s of family 51 (GT51). [[DD-Transpeptidase|Transpeptidase]]s cross link the chains and form a net-like peptidoglycan macromolecule. The resulting glycopeptide is an essential part of the envelope of many bacteria.
Lipid II was estimated to exist at a concentration of less than 2000 molecules per bacterial cell.<ref name=JBac>{{cite journal|author1=Y. van Heijenoort|author2= M. Gomez|author3=M. Derrien|author4= J. Ayala|author5=J. van Heijenoort|title=Membrane intermediates in the peptidoglycan metabolism of Escherichia coli: possible roles of PBP 1b and PBP 3.|journal=J. Bacteriol.|date=1992|volume=174|pages=3549–3557;}}</ref>
Lipid II was estimated to exist at a concentration of less than 2000 molecules per bacterial cell.<ref name=JBac>{{cite journal|author1=Y. van Heijenoort|author2= M. Gomez|author3=M. Derrien|author4= J. Ayala|author5=J. van Heijenoort|title=Membrane intermediates in the peptidoglycan metabolism of Escherichia coli: possible roles of PBP 1b and PBP 3.|journal=J. Bacteriol.|date=1992|volume=174|issue= 11|pages=3549–3557|doi= 10.1128/jb.174.11.3549-3557.1992|pmid= 1592809|pmc= 206040}}</ref>


Lipid II biosynthesis is functional and essential even in organisms without a cell wall like [[Chlamydia (bacterium)|''Chlamydia'']] and ''[[Wolbachia]]''. It has been hypothesized that maintaining lipid II biosynthesis reflects its role in prokaryotic [[cell division]].<ref name=MM>{{cite journal|vauthors=Henrichfreise B, Schiefer A, Schneider T |title=Functional conservation of the lipid II biosynthesis pathway in the cell wall-less bacteria Chlamydia and Wolbachia: why is lipid II needed?|journal=Mol Microbiol|date=September 2009| volume=73| issue=5| pages=913–23| doi=10.1111/j.1365-2958.2009.06815.x|display-authors=etal}}</ref>
Lipid II biosynthesis is functional and essential even in organisms without a cell wall like [[Chlamydia (bacterium)|''Chlamydia'']] and ''[[Wolbachia]]''. It has been hypothesized that maintaining lipid II biosynthesis reflects its role in prokaryotic [[cell division]].<ref name=MM>{{cite journal|vauthors=Henrichfreise B, Schiefer A, Schneider T |title=Functional conservation of the lipid II biosynthesis pathway in the cell wall-less bacteria Chlamydia and Wolbachia: why is lipid II needed?|journal=Mol Microbiol|date=September 2009| volume=73| issue=5| pages=913–23| doi=10.1111/j.1365-2958.2009.06815.x|pmid=19656295|display-authors=etal|doi-access=free}}</ref>
In the discovery and mechanism of assembly of [[pilus|pili]] in gram positive bacteria Lipid II has been implicated as a crucial structural molecule. It anchors the pili during or after polymerization of the pilus components.<ref>Pili in Gram-positive pathogens, Nature, vol 4, pg 513</ref>
In the discovery and mechanism of assembly of [[pilus|pili]] in gram positive bacteria Lipid II has been implicated as a crucial structural molecule. It anchors the pili during or after polymerization of the pilus components.<ref>Pili in Gram-positive pathogens, Nature, vol 4, pg 513</ref>


==Antibiotics==
==Antibiotics==
Since Lipid II must be flipped outside the cytoplasmic membrane before incorporation of its disaccharide-peptide unit into peptidoglycan, it is a relatively accessible target for antibiotics. These antibiotics fight bacteria by either directly inhibiting the peptidoglycan synthesis, or by binding to lipid II to form destructive pores in the cytoplasmic membrane.<ref name=mmbr>{{cite journal|author1=Heijenoort J|title=Lipid Intermediates in the Biosynthesis of Bacterial Peptidoglycan|journal=Microbiol Mol Biol Rev|url=http://mmbr.asm.org/content/71/4/620.full#title12|doi=10.1128/MMBR.00016-07|date=December 2007|accessdate=13 January 2015|volume=71|pages=620–635|pmc=2168651}}</ref> Examples of antibiotics that target Lipid II include:
Since Lipid II must be flipped outside the cytoplasmic membrane before incorporation of its disaccharide-peptide unit into peptidoglycan, it is a relatively accessible target for antibiotics. These antibiotics fight bacteria by either directly inhibiting the peptidoglycan synthesis, or by binding to lipid II to form destructive pores in the cytoplasmic membrane.<ref name=mmbr>{{cite journal|author1=Heijenoort J|title=Lipid Intermediates in the Biosynthesis of Bacterial Peptidoglycan|journal=Microbiol Mol Biol Rev|url= |doi=10.1128/MMBR.00016-07|pmid=18063720|date=December 2007|volume=71|issue=4|pages=620–635|pmc=2168651}}</ref> Examples of antibiotics that target Lipid II include:
*[[Vancomycin]] and its synthetic derivatives<ref name=mmbr/>
*[[Vancomycin]] and its synthetic derivatives<ref name=mmbr/>
*[[Ramoplanin]]<ref name=mmbr/>
*[[Ramoplanin]]<ref name=mmbr/>
*Several [[lantibiotics]], including the common food preservative [[nisin]]<ref name=plefa>{{cite journal|vauthors=de Kruijff B, van Dam V, Breukink E|title=Lipid II: A central component in bacterial cell wall synthesis and a target for antibiotics|journal=Prostaglandins Leukot Essent Fatty Acids|date=12 November 2008|pmid=19008088|doi=10.1016/j.plefa.2008.09.020|volume=79|pages=117–21}}</ref>
*Several [[lantibiotics]], including the common food preservative [[nisin]]<ref name=plefa>{{cite journal|vauthors=de Kruijff B, van Dam V, Breukink E|title=Lipid II: A central component in bacterial cell wall synthesis and a target for antibiotics|journal=Prostaglandins Leukot Essent Fatty Acids|date=12 November 2008|pmid=19008088|doi=10.1016/j.plefa.2008.09.020|volume=79|issue=3–5|pages=117–21|hdl=1874/33263|hdl-access=free}}</ref>
*[[Teixobactin]]<ref name="teixo">{{cite journal | first1=Gerard| last1=Wright| title = Antibiotics: An irresistible newcomer | journal = [[Nature (journal)|Nature]] | volume = 517| issue = | date = 7 January 2015 | pmid = 25561172| doi = 10.1038/nature14193 | pages=442–444}}</ref>
*[[Teixobactin]]<ref name="teixo">{{cite journal | first1=Gerard| last1=Wright| title = Antibiotics: An irresistible newcomer | journal = [[Nature (journal)|Nature]] | volume = 517| issue = 7535| date = 7 January 2015 | pmid = 25561172| doi = 10.1038/nature14193 | pages=442–444| bibcode=2015Natur.517..442W| s2cid=4464402| doi-access =free}}</ref>
*[[Copsin]]
*[[Copsin]]
*Human [[alpha defensins]]
*Human [[alpha defensins]]
Line 65: Line 67:
===Binding===
===Binding===
The D-Ala-D-Ala terminus is used by [[glycopeptide]] antibiotic [[vancomycin]] to inhibit lipid I- and lipid II-consuming peptidoglycan synthesis; in vancomycin-resistant strains vancomycin cannot bind, because a crucial hydrogen bond is lost.
The D-Ala-D-Ala terminus is used by [[glycopeptide]] antibiotic [[vancomycin]] to inhibit lipid I- and lipid II-consuming peptidoglycan synthesis; in vancomycin-resistant strains vancomycin cannot bind, because a crucial hydrogen bond is lost.
[[Oritavancin]] also uses the D-Ala-D-Ala terminus, but in addition it uses the crossbridge and D-iso-glutamine in position 2 of the lipid II stem peptide, as present in a number of Gram-positive pathogens, like staphylococci and [[enterococcus|enterococci]]. The increased binding of oritavancin through amidation of lipid II can compensate for the loss of a crucial hydrogen bond in vancomycin-resistant strains,<ref name=aac>{{cite journal|vauthors=Münch D, Engels I, Müller A, Reder-Christ K, Falkenstein-Paul H, Bierbaum G, Grein F, Bendas G, Sahl HG, Schneider T|title=Structural variations of the cell wall precursor lipid II - Influence on binding and activity of the lipoglycopeptide antibiotic oritavancin|journal=Antimicrobial Agents and Chemotherapy|url=http://aac.asm.org/content/early/2014/11/11/AAC.02663-14.long|doi=10.1128/AAC.02663-14|date=17 November 2014|accessdate=10 January 2015|volume=59|pages=772–781|pmid=25403671|pmc=4335874}}</ref>
[[Oritavancin]] also uses the D-Ala-D-Ala terminus, but in addition it uses the crossbridge and D-iso-glutamine in position 2 of the lipid II stem peptide, as present in a number of Gram-positive pathogens, like staphylococci and [[enterococcus|enterococci]]. The increased binding of oritavancin through amidation of lipid II can compensate for the loss of a crucial hydrogen bond in vancomycin-resistant strains,<ref name=aac>{{cite journal|vauthors=Münch D, Engels I, Müller A, Reder-Christ K, Falkenstein-Paul H, Bierbaum G, Grein F, Bendas G, Sahl HG, Schneider T|title=Structural variations of the cell wall precursor lipid II - Influence on binding and activity of the lipoglycopeptide antibiotic oritavancin|journal=Antimicrobial Agents and Chemotherapy|doi=10.1128/AAC.02663-14|date=17 November 2014|volume=59|issue=2|pages=772–781|pmid=25403671|pmc=4335874}}</ref>


Lantibiotics recognize lipid-II by its [[pyrophosphate]].<ref name=sim/>
Lantibiotics recognize lipid-II by its [[pyrophosphate]].<ref name=sim/>


Lipid II interacts with human [[alpha defensin]]s, a class of [[antimicrobial peptide]]s, such as [[Defensin, alpha 1]]. The latter has been used to describe and predict binding of synthetic low-molecular weight compounds created as possible therapeutic agents in treating of Gram-positive infections.<ref name=PLoS>{{cite journal|vauthors=Varney KM, Bonvin AM, Pazgier M|title=Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II.|journal=PLoS Pathog|date=2013|volume=9|issue=11|pages=e1003732.|doi=10.1371/journal.ppat.1003732|PMC=3820767|pmid=24244161|display-authors=etal}}</ref>
Lipid II interacts with human [[alpha defensin]]s, a class of [[antimicrobial peptide]]s, such as [[Defensin, alpha 1]]. The latter has been used to describe and predict binding of synthetic low-molecular weight compounds created as possible therapeutic agents in treating of Gram-positive infections.<ref name=PLoS>{{cite journal|vauthors=Varney KM, Bonvin AM, Pazgier M|title=Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II.|journal=PLOS Pathog|date=2013|volume=9|issue=11|pages=e1003732|doi=10.1371/journal.ppat.1003732|pmc=3820767|pmid=24244161|display-authors=etal |doi-access=free }}</ref>

⚫
[[Penicillin-binding protein]] 4 exchanges d-amino acids into Lipid II (and Lipid I), acting as a transpeptidase in vitro.<ref name=JACS>{{cite journal|vauthors=Qiao Y, Lebar MD, Schirner K, Schaefer K, Tsukamoto H, Kahne D, Walker S|title=Detection of lipid-linked peptidoglycan precursors by exploiting an unexpected transpeptidase reaction.|journal=J Am Chem Soc|date=22 October 2014|volume=136|issue=42|pages=14678–81|doi=10.1021/ja508147s|pmid=25291014|pmc=4210121}}</ref>


⚫
[[Penicillin-binding protein]] 4 exchanges d-amino acids into Lipid II (and Lipid I), acting as a transpeptidase in vitro.<ref name=JACS>{{cite journal|vauthors=Qiao Y, Lebar MD, Schirner K, Schaefer K, Tsukamoto H, Kahne D, Walker S|title=Detection of lipid-linked peptidoglycan precursors by exploiting an unexpected transpeptidase reaction.|journal=J Am Chem Soc|date=22 October 2014|volume=136|issue=42|pages=14678–81|doi=10.1021/ja508147s|pmc=4210121}}</ref>


==References==
==References==
{{reflist|2}}
{{reflist|25em}}


==External links==
==External links==
Line 80: Line 83:


[[Category:Lipids]]
[[Category:Lipids]]
[[Category:Cell anatomy]]

Latest revision as of 02:32, 2 October 2024

Lipid II
Names
Systematic IUPAC name
(2R,5R,8S,13R,16S,19R)-19-{[(2R,3R,4R,5S,6R)-3-Acetamido-5-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2-[(1,3-dihydroxy-1,3-dioxo-3-{[(2Z,6Z,10Z,14Z,18Z,22Z,26Z,30Z,34E,38E,42E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaen-1-yl]oxy}-1λ5,3λ5-diphosphoxan-1-yl)oxy]-6-(hydroxymethyl)oxan-4-yl]oxy}-8-(4-aminobutyl)-13-carboxy-2,5,16-trimethyl-4,7,10,15,18-pentaoxo-3,6,9,14,17-pentaazaicosan-1-oic acid
Identifiers
3D model (JSmol)
9039417
ChEBI
ChemSpider
KEGG
  • InChI=1S/C94H156N8O26P2/c1-59(2)31-21-32-60(3)33-22-34-61(4)35-23-36-62(5)37-24-38-63(6)39-25-40-64(7)41-26-42-65(8)43-27-44-66(9)45-28-46-67(10)47-29-48-68(11)49-30-50-69(12)54-56-122-129(118,119)128-130(120,121)127-94-82(100-75(18)106)86(85(79(58-104)125-94)126-93-81(99-74(17)105)84(109)83(108)78(57-103)124-93)123-73(16)89(112)96-71(14)88(111)102-77(92(116)117)52-53-80(107)101-76(51-19-20-55-95)90(113)97-70(13)87(110)98-72(15)91(114)115/h31,33,35,37,39,41,43,45,47,49,54,70-73,76-79,81-86,93-94,103-104,108-109H,19-30,32,34,36,38,40,42,44,46,48,50-53,55-58,95H2,1-18H3,(H,96,112)(H,97,113)(H,98,110)(H,99,105)(H,100,106)(H,101,107)(H,102,111)(H,114,115)(H,116,117)(H,118,119)(H,120,121)/b60-33+,61-35+,62-37-,63-39-,64-41-,65-43-,66-45-,67-47-,68-49-,69-54-/t70-,71+,72-,73-,76+,77-,78-,79-,81-,82-,83-,84-,85-,86-,93+,94-/m1/s1 checkY
    Key: ULXTYUPMJXVUHQ-OVTFQNCVSA-N checkY
  • CC(C(=O)NC(CCC(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(C)C(=O)O)C(=O)O)NC(=O)C(C)OC1C(C(OC(C1OC2C(C(C(C(O2)CO)O)O)NC(=O)C)CO)OP(=O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)NC(=O)C
Properties
C94H156N8O26P2
Molar mass 1876.23 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Lipid II is a precursor molecule in the synthesis of the cell wall of bacteria. It is a peptidoglycan, which is amphipathic and named for its bactoprenol hydrocarbon chain, which acts as a lipid anchor, embedding itself in the bacterial cell membrane. Lipid II must translocate across the cell membrane to deliver and incorporate its disaccharide-pentapeptide "building block" into the peptidoglycan mesh. Lipid II is the target of several antibiotics.

A number of analogous compounds are produced via a similar pathway in some bacteria, giving rise to cell wall modifications. See EC 2.4.1.227 for more information.[2]

Synthesis

[edit]

In peptidoglycan biosynthetic pathway

[edit]

Lipid II is the final intermediate in peptidoglycan synthesis. It is formed when the MurG transferase catalyzes addition of N-acetylglucosamine (GlcNAc) to Lipid I, resulting in a complete disaccharide-pentapeptide monomer with a bactoprenol-pyrophosphate anchor. This occurs on the inside of the cytoplasmic membrane, where the bactoprenol chain is embedded in the inner leaflet of the bilayer. Lipid II is then transported across the membrane by a flippase, to expose the disaccharide-pentapeptide monomer, which is the pentapeptide stem consisting of L-Ala-γ-D-Glu-m-DAP-D-Ala-D-Ala between GlcNAc and N-acetylmuramic acid (MurNAc), for polymerization and cross-linking into peptidoglycan. The remaining bactoprenol-pyrophosphate is then recycled to the interior of the membrane. Lipid II has been referred to as the "shuttle carrier" of peptidoglycan "building blocks'.[3]

The essential MurJ flippase that translocates lipid II across the cytoplasmic membrane was only published in July 2014, after decades of searching.[4] The discovery remains somewhat controversial as assay results are conflicting; FtsW (EC 2.4.1.129) was proposed as an alternative, with evidence strongly favoring the MurJ side since 2019.[5]

Artificial production

[edit]

A method for artificial production of lipid II has been described. For synthesis of lipid II from UDP-MurNAc pentapeptide and undecaprenol, the enzymes MraY, MurG, and undecaprenol kinase can be used.[6] Synthetic Lipid II analogues are used in experiments studying how it interacts with and binds molecules.[7] Significant quantities of the important peptidoglycan precursor have also be isolated, following accumulation in bacterial cells.[8]

Functions

[edit]

Polymers of lipid II form a linear glycan chain. This reaction is catalyzed by the glycosyltransferases of family 51 (GT51). Transpeptidases cross link the chains and form a net-like peptidoglycan macromolecule. The resulting glycopeptide is an essential part of the envelope of many bacteria. Lipid II was estimated to exist at a concentration of less than 2000 molecules per bacterial cell.[9]

Lipid II biosynthesis is functional and essential even in organisms without a cell wall like Chlamydia and Wolbachia. It has been hypothesized that maintaining lipid II biosynthesis reflects its role in prokaryotic cell division.[10]

In the discovery and mechanism of assembly of pili in gram positive bacteria Lipid II has been implicated as a crucial structural molecule. It anchors the pili during or after polymerization of the pilus components.[11]

Antibiotics

[edit]

Since Lipid II must be flipped outside the cytoplasmic membrane before incorporation of its disaccharide-peptide unit into peptidoglycan, it is a relatively accessible target for antibiotics. These antibiotics fight bacteria by either directly inhibiting the peptidoglycan synthesis, or by binding to lipid II to form destructive pores in the cytoplasmic membrane.[12] Examples of antibiotics that target Lipid II include:

Binding

[edit]

The D-Ala-D-Ala terminus is used by glycopeptide antibiotic vancomycin to inhibit lipid I- and lipid II-consuming peptidoglycan synthesis; in vancomycin-resistant strains vancomycin cannot bind, because a crucial hydrogen bond is lost. Oritavancin also uses the D-Ala-D-Ala terminus, but in addition it uses the crossbridge and D-iso-glutamine in position 2 of the lipid II stem peptide, as present in a number of Gram-positive pathogens, like staphylococci and enterococci. The increased binding of oritavancin through amidation of lipid II can compensate for the loss of a crucial hydrogen bond in vancomycin-resistant strains,[15]

Lantibiotics recognize lipid-II by its pyrophosphate.[3]

Lipid II interacts with human alpha defensins, a class of antimicrobial peptides, such as Defensin, alpha 1. The latter has been used to describe and predict binding of synthetic low-molecular weight compounds created as possible therapeutic agents in treating of Gram-positive infections.[16]

Penicillin-binding protein 4 exchanges d-amino acids into Lipid II (and Lipid I), acting as a transpeptidase in vitro.[17]


References

[edit]
  1. ^ Senf, L.; Schmidt, U.; Anger, G. (1 October 1977). [339578-22-2 "[Clearance computation from the blood level following a single injection of 125-I-hippuran]"]. Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete. pp. 508–513. {{cite web}}: Check |url= value (help)
  2. ^ "MetaCyc EC 2.4.1.227". biocyc.org.
  3. ^ a b Anton Chugunov; Darya Pyrkova; Dmitry Nolde; Anton Polyansky; Vladimir Pentkovsky; Roman Efremov (Apr 16, 2013). "Lipid-II forms potential "landing terrain" for lantibiotics in simulated bacterial membrane". Sci. Rep. 3: 1678. Bibcode:2013NatSR...3E1678C. doi:10.1038/srep01678. PMC 3627190. PMID 23588060.
  4. ^ Lok-To Sham; Emily K. Butler; Matthew D. Lebar; et al. (11 July 2014). "MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis". Science. 345 (6193): 220–222. Bibcode:2014Sci...345..220S. doi:10.1126/science.1254522. PMC 4163187. PMID 25013077.
  5. ^ "TCDB 2.A.66.4.3". tcdb.org.
  6. ^ Huang LY, Huang SH, Chang YC, Cheng WC, Cheng TJ, Wong CH (28 July 2014). "Enzymatic synthesis of lipid II and analogues". Angew Chem Int Ed Engl. 53 (31): 8060–5. doi:10.1002/anie.201402313. PMID 24990652.
  7. ^ t Hart P, Oppedijk S, Breukink E, Martin NI (2016). "New Insights into Nisin's Antibacterial Mechanism Revealed by Binding Studies with Synthetic Lipid II Analogues". Biochemistry. 55 (1): 232–7. doi:10.1021/acs.biochem.5b01173. PMID 26653142.
  8. ^ Qiao Y, Srisuknimit V, Rubino F, Schaefer K, Nuiz R, Walker S, Kahne D (2017). "Lipid II overproduction allows direct assay of transpeptidase inhibition by b-lactams". Nature Chemical Biology. 13 (7): 793–798. doi:10.1038/nchembio.2388. PMC 5478438. PMID 28553948.
  9. ^ Y. van Heijenoort; M. Gomez; M. Derrien; J. Ayala; J. van Heijenoort (1992). "Membrane intermediates in the peptidoglycan metabolism of Escherichia coli: possible roles of PBP 1b and PBP 3". J. Bacteriol. 174 (11): 3549–3557. doi:10.1128/jb.174.11.3549-3557.1992. PMC 206040. PMID 1592809.
  10. ^ Henrichfreise B, Schiefer A, Schneider T, et al. (September 2009). "Functional conservation of the lipid II biosynthesis pathway in the cell wall-less bacteria Chlamydia and Wolbachia: why is lipid II needed?". Mol Microbiol. 73 (5): 913–23. doi:10.1111/j.1365-2958.2009.06815.x. PMID 19656295.
  11. ^ Pili in Gram-positive pathogens, Nature, vol 4, pg 513
  12. ^ a b c Heijenoort J (December 2007). "Lipid Intermediates in the Biosynthesis of Bacterial Peptidoglycan". Microbiol Mol Biol Rev. 71 (4): 620–635. doi:10.1128/MMBR.00016-07. PMC 2168651. PMID 18063720.
  13. ^ de Kruijff B, van Dam V, Breukink E (12 November 2008). "Lipid II: A central component in bacterial cell wall synthesis and a target for antibiotics". Prostaglandins Leukot Essent Fatty Acids. 79 (3–5): 117–21. doi:10.1016/j.plefa.2008.09.020. hdl:1874/33263. PMID 19008088.
  14. ^ Wright, Gerard (7 January 2015). "Antibiotics: An irresistible newcomer". Nature. 517 (7535): 442–444. Bibcode:2015Natur.517..442W. doi:10.1038/nature14193. PMID 25561172. S2CID 4464402.
  15. ^ Münch D, Engels I, Müller A, Reder-Christ K, Falkenstein-Paul H, Bierbaum G, Grein F, Bendas G, Sahl HG, Schneider T (17 November 2014). "Structural variations of the cell wall precursor lipid II - Influence on binding and activity of the lipoglycopeptide antibiotic oritavancin". Antimicrobial Agents and Chemotherapy. 59 (2): 772–781. doi:10.1128/AAC.02663-14. PMC 4335874. PMID 25403671.
  16. ^ Varney KM, Bonvin AM, Pazgier M, et al. (2013). "Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II". PLOS Pathog. 9 (11): e1003732. doi:10.1371/journal.ppat.1003732. PMC 3820767. PMID 24244161.
  17. ^ Qiao Y, Lebar MD, Schirner K, Schaefer K, Tsukamoto H, Kahne D, Walker S (22 October 2014). "Detection of lipid-linked peptidoglycan precursors by exploiting an unexpected transpeptidase reaction". J Am Chem Soc. 136 (42): 14678–81. doi:10.1021/ja508147s. PMC 4210121. PMID 25291014.
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Lipid_II&oldid=1248902768"